Systemic therapy for advanced hepatocellular carcinoma: an update.

Area of Science:

• Hepatocellular Carcinoma Research
• Oncology Therapeutics
• Systemic Cancer Treatment

Background:

• Advanced hepatocellular carcinoma (HCC) presents a significant challenge due to limited effective systemic therapies.
• Sorafenib is the sole FDA-approved first-line treatment, offering a modest increase in overall survival.
• Regorafenib has shown efficacy in second-line treatment, but an unmet need for advanced HCC therapies persists.

Purpose of the Study:

• To review current systemic therapeutic options for advanced hepatocellular carcinoma (HCC).
• To highlight the limitations of existing treatments and the need for novel therapeutic strategies.
• To discuss the potential of targeting specific HCC subclasses and emerging immunotherapies.

Main Methods:

• Review of clinical trial data for sorafenib and regorafenib in HCC treatment.
• Analysis of research into genetic pathways and targeted therapies for HCC.
• Exploration of HCC etiology-specific treatments and immunotherapy approaches.

Main Results:

• Sorafenib improved overall survival by 3 months in first-line treatment.
• Regorafenib demonstrated improved overall survival in second-line treatment after sorafenib progression.
• Targeted therapies for proliferation, metastasis, angiogenesis, and metabolite use have shown minimal success.

Conclusions:

• Despite current treatments, advanced HCC requires more effective systemic therapies.
• Understanding HCC subclasses and their distinct pathways is crucial for developing targeted treatments.
• Immunotherapy shows promise, necessitating further research to identify key pathways for future drug development.